Background
==========

Multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD) are autoimmune demyelinating disorder of the central nervous system. Only a few biomarkers are available in the clinical practice, such as cerebrospinal fluid oligoclonal bands and serum anti-aquaporin 4 antibodies. Thus, there is a significant unmet need for biomarkers to assess diagnosis and prognosis. MicroRNAs, a kind of small non-coding RNA present in stable form in the human blood, have attracted much attention as novel diagnostic biomarkers for many diseases, such as tumors and autoimmune diseases \[[@b1-medscimonit-23-2565]\]. Functionally, these miRNAs regulate gene expression involving cell division, metabolism, stress response, and angiogenesis \[[@b2-medscimonit-23-2565]--[@b5-medscimonit-23-2565]\]. Others play roles in proliferation, invasion and migration of cancer \[[@b6-medscimonit-23-2565]--[@b10-medscimonit-23-2565]\].

Previous studies demonstrated that miRNA expression profiles in whole blood or purified blood cell subtypes are correlated with MS and that circulating miRNAs are differentially expressed in different stages of MS \[[@b11-medscimonit-23-2565]--[@b14-medscimonit-23-2565]\], making them easily accessible for monitoring MS \[[@b15-medscimonit-23-2565]\]. Moreover, recent study identified a set of differentially expressed miRNAs in whole blood that may discriminate neuromyelitis optica spectrum disorders (NMOSD) from relapsing- remitting multiple sclerosis (RRMS) in Europeans \[[@b16-medscimonit-23-2565]\]. However, there are less reports on the correlation between miRNAs and clinical features and pathology of NMOSD. For instance, it is unclear how certain miRNAs contribute specifically to brain pathology in NMOSD.

So far there is no accurate epidemiological data on NMOSD worldwide, but it is well known that NMOSD accounts for a much higher proportion of idiopathic inflammatory demyelinating diseases (IIDDS) (40%) in Asians than in white populations (1%) \[[@b17-medscimonit-23-2565]\]. Regarding a predominance of NMOSD in Chinese and remarkable differences of clinical features and genetic backgrounds between Eastern and Western populations \[[@b18-medscimonit-23-2565]\], we sought to re-evaluate the correlation of these miRNAs with NMOS and RRMS Chinese. We also analyzed the association of these miRNAs with the clinical features of these diseases.

Material and Methods
====================

Patients
--------

A total of 62 patients were diagnosed and treated in The First Affiliated Hospital of Fujian Medical University from November 2013 to July 2016. Twenty healthy adults (18 females, 2 males, aged 44.7±9.8 years) were recruited as normal controls. Among all the cases, 45 were diagnosed as NMOSD according to 2015 International Consensus Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorders \[[@b18-medscimonit-23-2565]\], and 17 were diagnosed with RRMS according to the McDonald 2010 criteria \[[@b19-medscimonit-23-2565]\] and 2016 MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines \[[@b20-medscimonit-23-2565]\]. We defined patients within 8 weeks after an acute attack with NMOSD or RRMS as active phase, more than 8 weeks as a stable phase according to the diagnostic criteria for MS \[[@b14-medscimonit-23-2565]\].

All clinical information including MRI and laboratory tests were collected and evaluated by senior neurologists with expertise in neuroimmunology. The clinical features of the 3 categories of patients were listed in [Table 1](#t1-medscimonit-23-2565){ref-type="table"}. The 2 patient groups were significantly different in age and female preponderance. Among 40 NMOSD patients who underwent anti-AQP4 antibody detection by cell-based transfection immunofluorescence assay (CBA, EUROIMMUM Medical Diagnostic, China Co. Ltd.), 34 (85.0%) were positive, the other 5 patients who did not make detection were diagnosed by AQP4 negative diagnostic criteria. Among 10 RRMS patients underwent anti-AQP4 antibody detection, none was positive. The proportion of B lymphocyte in peripheral blood mononuclear cells (PBMCs) was detected in 23 NMOSD patients, among which 8 were decreased and 12 were increased. 15 of 36 NMOSD patients underwent other autoantibodies detection, including ANA, ANA spectrum, dsDNA, ACA, AnCA, and 15(41.7%) were positive. Among 15 RRMS patients underwent autoantibodies detection, 1 (6.7%) was positive. Parenchymal lesions were found in 19(42.2%) NMOSD cases among which 14(31.1%) met the neuroimaging criteria of the 2015 International Consensus Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorders and 2016 MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. These lesions located extensively in the brain regions, including medulla oblongata and area postrema (6/14), midbrain (2/14), thalamus (1/14), periaqueductal, lateral ventricle and the third ventricle (3/14), corpus callosum (3/14) and cerebral hemisphere (4/14). All NMOSD cases received 500--1000 mg of methyl prednisolone treatment in acute stage, which were gradually reduced to 10mg as maintenance dosage for 3 to 36 months. Thirteen patients were treated with gamma globulin 400 mg/kg intravenous injection for 5 days together with prednisolone in the acute phase. Twelve cases used azathioprine 100--150 mg/day for 3 to 60 months, and 3 of them also used cyclosporine 100--150 mg/day for 12 to 36 months. This study was approved by the Ethics Committee of The First Affiliated Hospital of Fujian Medical University (ID: clinical research 2014y0022) and written informed consent was obtained from all study participants.

Selection of miRNAs for measurement
-----------------------------------

A total of 9 miRNAs were selected for verification in our study, including miR-15b-3p (chr3: 160404588-160404685), miR-22b-5p (chr5: 13813148-13813229), miR-30b-5p (chr8: 134800520-134800607), miR-101-5p (chr1: 65058434-65058508), miR-126-5p (chr9: 136670602-136670686), miR-223-5p (chrX: 66018870-66018979), miR-335-3p (chr7: 130496111-130496204), miR-576-5p (chr4: 109488698-109488795) and miR-660-5p (chrX: 50013241-50013337). All of them showed significantly different expression levels in both NMOSD *vs.* CIS/RRMS and NMOSD *vs.* healthy controls in whole blood according to the Keller's study \[[@b23-medscimonit-23-2565]\].

Peripheral blood RNA isolation and qRT-PCR
------------------------------------------

A 5-ml blood sample was collected in EDTA tubes from each of the participants and stored at −80°C. MiRNAs was extracted from peripheral whole blood using Tri-Reagent (Life Technologies) according to the manufacturer's instructions. The purity and concentration of RNA were determined using NanoDrop One (Thermo Scientific). For quantitative detection of miRNA by RT-PCR, purified whole blood miRNA was converted to cDNA by reverse transcription reactions using TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems) and miRNA-specific stem-loop primers were supplied by the TaqMan MicroRNA Assays (Applied Biosystems).

Selected miRNAs were measured by quantitative real-time reverse transcription polymerase chain reaction (RT-PCR) using the qPCR Master Mix (Promega) and QuantStudio^®^ 5 Real-Time PCR System (Applied Biosystems) according to the manufacturer's instructions. The reactions were incubated in a 96-well optical plate at 95°C for 5 min, followed by 40 cycles at 95°C for 15 s, and 60°C for 40 s. Reactions were performed in triplicate. The cycle threshold (CT) was recorded, which was defined as the number of PCR cycles required for the fluorescent signal to be higher than a threshold indicating baseline variability. Cel-miR-39-3p was chosen as the exogenous reference control. Amplification and melting working curves of all miRNAs are shown in [Supplementary Figures 1](#s1-medscimonit-23-2565){ref-type="supplementary-material"} and [2](#s2-medscimonit-23-2565){ref-type="supplementary-material"}. Relative changes of miRNA expression were represented by 2-ΔCT.

Bioinformatics analysis
-----------------------

We used the miEAA (*<http://www.ccb.uni-saarland.de/mieaa_tool/>*) as a tool to characterize the association of the miRNAs with molecular pathways. MiEAA is based on GeneTrail \[[@b24-medscimonit-23-2565]\] and used for standard enrichment analyses, such as over-representation analysis or gene set enrichment analysis in the context of miRNAs. Adjusted *p* values \<0.05 were considered significant enrichment.

Statistical analysis
--------------------

Numeric data were expressed as mean ± standard deviation (SD). Statistical analyses were performed using the professional statistical computer software, GraphPad Prism 5. Differences between groups were tested using the one-way ANOVA rank test or two-tailed student t-test, P\<0.05 for two-tailed test was set as the level of statistical significance. Post hoc testing was carried out between the samples. The P values were corrected by the Tukey-Kramer standard.

Results
=======

Clinical features of the NMOSD and RRMS patients
------------------------------------------------

Clinical features of the patients with NMOSD, RRMS are listed in [Table 1](#t1-medscimonit-23-2565){ref-type="table"} and compared with healthy controls (HCs). Compared to RRMS, NMOSD patients had older onset (P=0.04), more significant female preponderance (P=0.02), higher frequency of recurrence (P=0.03), as well as higher positive rate of anti-AQP4 antibody (P\<0.0001) and autoantibody (P=0.002).

Alterations of the miRNA expression level in NMOSD and RRMS
-----------------------------------------------------------

The levels of all measured miRNAs are shown in [Figure 1](#f1-medscimonit-23-2565){ref-type="fig"}. As compared with healthy controls (HCs), miR-22-5p, miR-30b-5p and miR-126-5p were down-regulated in NMOSD (P=0.02, P\<0.001 and P=0.04, respectively). In contrast, miR-101-5p and miR-126-5p were expressed at higher levels in RRMS (P=0.03 and P=0.04) than in controls. Moreover, the levels of miR-101-5p, miR-126-5p as well as miR-660-5p, were significantly higher in RRMS than in NMOSD (P=0.04, 0.01 and 0.02, respectively)**.**

Correlation between miRNA levels and the clinical features of NMOSD
-------------------------------------------------------------------

Based on a significant correlation between miRNAs with the development of NMOSD, we next analyzed the correlation between miRNA expression level and clinical features of NMOSD, including age, gender, disease duration, recurrence times, severity of visual impairment, EDSS score, AQP4 antibody titers, proportion of B lymphocyte subsets, and MRI findings. By comparing the miRNA levels in patients displaying each of the two-categorized clinical features, we found that the level of miR-576-5p was significantly higher in patients underwent relapse for ≤3 times than those for ≥4 times (P=0.01). In addition, its level was significantly higher in patients suffered from a severe visual impairment (visual sight ≤0.1) (P=0.003). Similar changes were revealed in the level of miR-223-5p in patients with more relapses and visual impairment, but with lower statistical significance (P=0.05 and 0.04, respectively). There was no significant correlation between the expression level of the remaining 7 miRNAs and the NMOSD features ([Table 2](#t2-medscimonit-23-2565){ref-type="table"}).

Correlation between miRNAs with intracranial lesions in NMOSD patients
----------------------------------------------------------------------

The demyelinating lesions in CNS of NMOSD are mainly confined within the optic nerve and spinal cord. However, it has been demonstrated that intracranial (IC) lesions are also common, and that different molecular mechanisms may account for cases with and without intracranial. Thus, we asked whether this difference may be related to miRNAs. To address this, we further divided the NMOSD patients into 2 subgroups, showing typical intracranial (IC) and without (non-IC) lesions according to MRI findings, and compared the miRNA levels of patients in RRMS patients. Among 45 NMOSD cases, 14 (31.1%) had typical intracranial lesions distributed widely in the white matters, including paraventricular, subcortical regions and corpus callosum. As shown in [Figure 2](#f2-medscimonit-23-2565){ref-type="fig"}, the levels of each of 9 miRNAs were lower in NMOSD patients with intracranial lesions (NMOSD-IC) than those without (NMOSD-non-IC). In addition, although the level of miR-15b-3p, miR-22b-5p, miR-30b-5p and miR-126b-5p were reduced in NMOSD as a whole, they were only significantly down-regulated in the NMOSD-IC subgroup, as compared with HCs. Similarly, only the NMOSD-IC patients showed lower miR-15b-3p, miR-30b-5p, miR-223-5p and miR-576b-5p levels than the NMOSD-non-IC patients. Interestingly, the level of miR-15b-5p was significantly lower in the NMOSD-IC patients than in RRMS and HCs, although its level in all NMOSD patients was not significantly different from patients with these groups ([Figure 1](#f1-medscimonit-23-2565){ref-type="fig"}). In contrast, there was no significant difference in the level of any of the 9 miRNAs between NMOSD-non-IC subgroup with RRMS, CIS and HCs. These results collectively suggested that it was the intracranial lesions in the NMOSD that correlate with the peripheral down-regulated miRNAs.

The utility of miRNAs in diagnosis and differentiation of NMOSD and RRMS
------------------------------------------------------------------------

The correlation between miRNA levels with the development and clinical features of NMOSD and RRMS suggested that they could help in diagnosing and differentiating them. To test how well these miRNAs discriminate individuals with demyelinating disease and controls and patients with different subtypes, we generated receiver operating characteristic (ROC) curves by plotting the sensitivity of the levels of these miRNAs against 1-specificity and calculating the area under the ROC curves (C statistic) for each population. As shown in [Figure 3](#f3-medscimonit-23-2565){ref-type="fig"}, the AUCs of miR-101-5p and miR-126-5p for discriminating NMOSD and control were 0.74 and 0.72(A), the AUCs of miR-101-5p, miR-126-5p and miR-660-5p for discriminating NMOSD from RRMS were 0.71, 0.72 and 0.69 respectively(B). When we combined these 3 miRNAs, the AUC was 0.72, 0.69, 0.71 and 0.72 in discriminating these 2 subtypes (C). We also calculated the AUC of ROC for miR-15-5p, miR-30-5p, miR-223-5p and miR-576-5p, alone and in combination, in discriminating NMOSD-IC and NMOSD-non-IC. It turned out that all the AUCs were \<0.8 (D). Combined, the results showed that none of the miRNA has enough power in the diagnosis and differential diagnosis of RRMS or NMOSD.

Enrichment of miRNAs in molecular pathways
------------------------------------------

For the 5 miRNAs differentially expressed in NMOSD patients as compared to controls or RRMS, we found the most enrichment of miRNAs in pathways in cancer (4 of 5 ranked on position 1). Moreover, the neurotrophin signaling pathway, though not ranked before many pathways, was shared by all the 5 miRNAs ([Supplementary Table 1](#s3-medscimonit-23-2565){ref-type="supplementary-material"})

Discussion
==========

NMOSD miRNA profiling was studied by next-generation sequencing (NGS), and the whole blood is thought to be an appropriate biospecimen for identification with neuroinflammatory diseases \[[@b16-medscimonit-23-2565]\]. Previous research showed that a part of the miRNAs we selected are associated with inflammatory disease (miR-15b-5p and miR-30b-5p), others are associated with autoimmune disease (miR-22-5p, miR-101-5p, miR-223-5p and miR-660-5p). MiRWalk database showed that all the 9 miRNAs were specifically enriched in neurotrophin signaling pathway. Signaling activated by neurotrophins leads to a series of neuronal functions, such as axonal growth, cell survival, differentiation, dendritic arborization, synapse formation, plasticity and axonal guidance \[[@b21-medscimonit-23-2565],[@b22-medscimonit-23-2565]\].

We found that some miRNAs (miR-22-5p, miR-30b-5p and miR-126-5p) were down-regulated in NMOSD, while others (miR-101-5p and miR-126-5p) were up-regulated in RRMS. Moreover, miR-223-5p and miR-576b-5p are associated with the certain clinical features in NMOSD, including the relapse and extent of visual impairment. MiR-30b-5p participates in restoration of injured optic nerve by regulating sema3A \[[@b23-medscimonit-23-2565]\]. However, we did not observe any different expression between the patients with relapse or visual impairment. Instead, we found that the miR-576b-5p and miR-223-5p levels were associated with severe visual damage. These results confirm that miRNAs are correlated with CNS inflammatory demyelinating diseases, yet different subtypes may have different miRNA profiles. Nonetheless, the numbers of the patients RRMS was too small and the results look preliminary.

A major strength of the study is the finding of a strong reverse correlation between the peripheral miRNA expression levels with the intracranial (IC) lesions in NMOSD. In fact, the down-regulation of miRNAs (such as miR-22b-5p, miR-30b-5p and miR-126b-5p) revealed in NMOSD were confined to patients with intracranial lesions. In contrast, there was no significant difference in any of the 9 miRNAs between NMOSD patients without intracranial lesions (NMOSD-non-IC), RRMS and HCs, suggesting that these miRNAs were only associated with the NMOSD- IC subgroup, but not all the NMOSD patients. These observations are contrasted with Keller's study, in which miR-30b-5p and miR-15b-5p were demonstrated as differentiation biomarkers for NMOSD and MS/CIS \[[@b20-medscimonit-23-2565]\]. The explanations for such differences could be multifold, the most important of which could be the considerable variation of incidence of intracranial lesions in NMOSD across different ethnicities, ranging from 12.5 to 89% \[[@b24-medscimonit-23-2565]--[@b29-medscimonit-23-2565]\]. The low incidence of intracranial lesions in our study might be a second explanation, with 5 non-specific small lesions locating in subcortical white matter and less than 3mm excluded from counting according to the MRI definition in the guidelines \[[@b20-medscimonit-23-2565]\]. However, we do not really understand the causes of NMOSD-IC. In MS patients, Th17/Th1 ≥1 relates to more lesions in brain than in spinal cord. Since NMOSD has more prominent imbalance of Th17/Th1 ratio than RRMS in the peripheral blood \[[@b30-medscimonit-23-2565]\], the intracranial lesion-specific miRNAs could be also involved in the regulation of Th17 polarization, which, in turn, may increase the permeability and destruction of BBB through ICAM, VCAM, MMP-9 \[[@b31-medscimonit-23-2565]--[@b33-medscimonit-23-2565]\]. Studies have demonstrated the important roles of miR-30b-5p in regulation of humoral immune response as an inflammatory related factor \[[@b4-medscimonit-23-2565]\], and bioinformatics analysis has also shown its acting on the IL-17 pathway. So, we consider that the cause of NMOSD-IC is the same as that of MS.

The functional significance of these NMOSD-associated miRNAs is not clear. It is interesting to find that these miRNAs were dominantly enriched in the cancer pathways and neurotrophin signaling pathway. Although there is no functional study confirming the involvement of cancer signaling pathway in inflammatory demyelinating diseases, there have been several studies confirming the role of neurotrophin factors, e.g. ciliary neurotrophic factor (CNTF) and p75NTR neurotrophin receptor, in multiple sclerosis \[[@b21-medscimonit-23-2565],[@b22-medscimonit-23-2565]\]. Thus, it is intriguing to further investigate what neurotrophin factor genes are targeted by these miRNAs and what mechanisms by which are involved in NMOSD. The difference of miRNA levels in whole blood between patients and controls suggest that they may be candidate diagnostic and differential biomarkers for these disease entities. However, the discriminating power of any of the miRNAs alone or in combination were not strong enough (all AUCs of ROC were less than 0.8) to ensure diagnosis and differentiation of NMOSD or RRMS. Nor was the discrimination ensured by any miRNA alone or in combination between NMOSD patients with intracranial lesions from those without at the diagnostic level.

Conclusions
===========

In summary, in a verification study, we confirmed that certain miRNAs in the whole blood are associated with NMOSD and RRMS with distinct profiles. We also demonstrated that miRNAs are only reversely correlated to the intracranial lesions in NMOSD. However, contrasting to Keller's study, none of the miRNA alone or in combination was powerful to ensure the diagnosis and differentiation of these disease subtypes. Future studies with expanded sample size (especially that of RRMS and CIS patients) and functional studies are needed to verify our findings.

Suplementary Files
==================

###### 

Amplification plot of the miRNAs. A is the amplification curves of miR-15b-3p, miR-22b-5p, miR-30b-5p and cel39, B is the amplification curves of miR-101-5p, miR-126-5p, miR-223-5p and cel39, C is the amplification curves of miR-335-3p, miR-576-5p, miR-660-5p and cel39.

###### 

Melting curves of the miRNAs. A is the melt curves of miR-15b-3p, miR-22b-5p, miR-30b-5p and cel39, B is the melt curves of miR-101-5p, miR-126-5p, miR-223-5p and cel39, C is the melt curves of miR-335-3p, miR-576-5p, miR-660-5p and cel39.

###### 

Enrichment of NMOSD-associated miRNAs in the molecular pathways.

  MiRNA            PathName                                                     PathFg   PathBg   GenomeFG   GenomeBG   P value       BH
  ---------------- ------------------------------------------------------------ -------- -------- ---------- ---------- ------------- -------------
  hsa-miR-101-5p   Insulin signaling pathway                                    87       139      8485       19747      2.34E-06      0.00045371
  hsa-miR-101-5p   Endocytosis                                                  109      187      8485       19747      1.65E-05      0.003114265
  hsa-miR-101-5p   Long term potentiation                                       48       71       8485       19747      2.36E-05      0.004468536
  hsa-miR-101-5p   Colorectal cancer                                            56       86       8485       19747      2.78E-05      0.005217761
  hsa-miR-101-5p   Neurotrophin signaling pathway                               78       129      8485       19747      4.52E-05      0.008402147
  hsa-miR-101-5p   Glioma                                                       44       65       8485       19747      4.89E-05      0.009095575
  hsa-miR-101-5p   Adherens junction                                            50       76       8485       19747      4.92E-05      0.009146105
  hsa-miR-101-5p   Pathways in cancer                                           176      330      8485       19747      8.55E-05      0.015646108
  hsa-miR-101-5p   Endometrial cancer                                           36       52       8485       19747      0.000115328   0.020759015
  hsa-miR-101-5p   Wnt signaling pathway                                        88       152      8485       19747      0.000143178   0.025628775
  hsa-miR-101-5p   Axon guidance                                                76       129      8485       19747      0.000185502   0.032833892
  hsa-miR-101-5p   T cell receptor signaling pathway                            66       110      8485       19747      0.000231552   0.040753187
  hsa-miR-101-5p   ErbB signaling pathway                                       55       89       8485       19747      0.000260331   0.045557925
  hsa-miR-101-5p   Chronic myeloid leukemia                                     47       75       8485       19747      0.000452969   0.077910691
  hsa-miR-101-5p   Phosphatidylinositol signaling system                        47       76       8485       19747      0.000695386   0.117520317
  hsa-miR-101-5p   Calcium signaling pathway                                    98       178      8485       19747      0.000741421   0.125300102
  hsa-miR-101-5p   Chemokine signaling pathway                                  103      189      8485       19747      0.000887525   0.148216608
  hsa-miR-101-5p   Ubiquitin mediated proteolysis                               76       134      8485       19747      0.000905223   0.151172313
  hsa-miR-101-5p   Melanoma                                                     44       71       8485       19747      0.000956101   0.158712713
  hsa-miR-101-5p   Renal cell carcinoma                                         44       71       8485       19747      0.000956101   0.158712713
  hsa-miR-101-5p   Non small cell lung cancer                                   35       54       8485       19747      0.000981599   0.16294541
  hsa-miR-101-5p   B cell receptor signaling pathway                            46       75       8485       19747      0.001018064   0.167980536
  hsa-miR-101-5p   Type II diabetes mellitus                                    32       49       8485       19747      0.001327476   0.215051074
  hsa-miR-101-5p   mTOR signaling pathway                                       34       53       8485       19747      0.001507004   0.241366957
  hsa-miR-101-5p   Gap junction                                                 53       90       8485       19747      0.001672357   0.265904786
  hsa-miR-101-5p   Prostate cancer                                              52       89       8485       19747      0.002335429   0.361991448
  hsa-miR-101-5p   Fc gamma R mediated phagocytosis                             56       97       8485       19747      0.00236227    0.366151908
  hsa-miR-101-5p   Adipocytokine signaling pathway                              42       70       8485       19747      0.00300524    0.453791189
  hsa-miR-101-5p   MAPK signaling pathway                                       139      272      8485       19747      0.003964632   0.582800901
  hsa-miR-101-5p   Pancreatic cancer                                            44       75       8485       19747      0.004398819   0.637828798
  hsa-miR-101-5p   Focal adhesion                                               106      203      8485       19747      0.004776226   0.687776614
  hsa-miR-101-5p   Purine metabolism                                            84       158      8485       19747      0.006105552   0.844734415
  hsa-miR-101-5p   GnRH signaling pathway                                       58       105      8485       19747      0.00745423    0.994695317
  hsa-miR-101-5p   Long term depression                                         40       73       8485       19747      0.027582947   1
  hsa-miR-101-5p   Jak STAT signaling pathway                                   82       156      8485       19747      0.009686644   1
  hsa-miR-101-5p   Small cell lung cancer                                       46       84       8485       19747      0.019339805   1
  hsa-miR-101-5p   SNARE interactions in vesicular transport                    23       39       8485       19747      0.032118483   1
  hsa-miR-101-5p   Acute myeloid leukemia                                       34       58       8485       19747      0.011708417   1
  hsa-miR-101-5p   Vascular smooth muscle contraction                           59       116      8485       19747      0.052274252   1
  hsa-miR-101-5p   Thyroid cancer                                               19       29       8485       19747      0.011984069   1
  hsa-miR-101-5p   Lysine degradation                                           27       45       8485       19747      0.015826415   1
  hsa-miR-101-5p   Epithelial cell signaling in Helicobacter pylori infection   38       71       8485       19747      0.047178139   1
  hsa-miR-101-5p   Metabolic pathways                                           499      1091     8485       19747      0.030975475   1
  hsa-miR-101-5p   VEGF signaling pathway                                       44       78       8485       19747      0.011418856   1
  hsa-miR-101-5p   Fc epsilon RI signaling pathway                              43       82       8485       19747      0.052777799   1
  hsa-miR-101-5p   Amyotrophic lateral sclerosis ALS                            30       55       8485       19747      0.055429268   1
  hsa-miR-101-5p   Primary bile acid biosynthesis                               11       16       8485       19747      0.033948998   1
  hsa-miR-101-5p   Nicotinate and nicotinamide metabolism                       16       24       8485       19747      0.01649091    1
  hsa-miR-101-5p   Non homologous end joining                                   10       13       8485       19747      0.014005601   1
  hsa-miR-101-5p   Inositol phosphate metabolism                                32       54       8485       19747      0.01154892    1
  hsa-miR-101-5p   Peroxisome                                                   44       79       8485       19747      0.015200198   1
  hsa-miR-101-5p   PPAR signaling pathway                                       39       70       8485       19747      0.021327693   1
  hsa-miR-101-5p   Cell adhesion molecules CAMs                                 67       133      8485       19747      0.050655518   1
  hsa-miR-101-5p   Nitrogen metabolism                                          16       23       8485       19747      0.009100855   1
  hsa-miR-101-5p   Aldosterone regulated sodium reabsorption                    24       42       8485       19747      0.045107589   1
  hsa-miR-101-5p   O Glycan biosynthesis                                        20       30       8485       19747      0.007542929   1
  hsa-miR-101-5p   Melanogenesis                                                54       102      8485       19747      0.026728523   1
  hsa-miR-101-5p   Lysosome                                                     62       121      8485       19747      0.040474391   1
  hsa-miR-101-5p   Tight junction                                               68       132      8485       19747      0.029075318   1
  hsa-miR-101-5p   Regulation of actin cytoskeleton                             103      212      8485       19747      0.056232548   1
  hsa-miR-101-5p   TGF beta signaling pathway                                   46       86       8485       19747      0.031594456   1
  hsa-miR-126-5p   Pathways in cancer                                           176      330      8124       19747      4.43E-06      0.000855946
  hsa-miR-126-5p   Small cell lung cancer                                       55       84       8124       19747      5.61E-06      0.001083654
  hsa-miR-126-5p   Neurotrophin signaling pathway                               76       129      8124       19747      3.35E-05      0.006370669
  hsa-miR-126-5p   Colorectal cancer                                            54       86       8124       19747      4.05E-05      0.007697755
  hsa-miR-126-5p   Chronic myeloid leukemia                                     48       75       8124       19747      5.29E-05      0.01004258
  hsa-miR-126-5p   Apoptosis                                                    53       87       8124       19747      0.000151403   0.027706725
  hsa-miR-126-5p   Ubiquitin mediated proteolysis                               76       134      8124       19747      0.000189394   0.034280231
  hsa-miR-126-5p   Insulin signaling pathway                                    78       139      8124       19747      0.000249692   0.044445215
  hsa-miR-126-5p   Pentose and glucuronate interconversions                     21       28       8124       19747      0.000289367   0.051279554
  hsa-miR-126-5p   ErbB signaling pathway                                       53       89       8124       19747      0.00034132    0.060413711
  hsa-miR-126-5p   Non small cell lung cancer                                   35       54       8124       19747      0.000373669   0.065765685
  hsa-miR-126-5p   MAPK signaling pathway                                       139      272      8124       19747      0.000528068   0.092411913
  hsa-miR-126-5p   Glioma                                                       40       65       8124       19747      0.000709157   0.123393247
  hsa-miR-126-5p   Ascorbate and aldarate metabolism                            19       26       8124       19747      0.000976366   0.168911356
  hsa-miR-126-5p   p53 signaling pathway                                        41       68       8124       19747      0.001096874   0.189759278
  hsa-miR-126-5p   Endocytosis                                                  98       187      8124       19747      0.001158089   0.200349415
  hsa-miR-126-5p   Type II diabetes mellitus                                    31       49       8124       19747      0.001447572   0.247534873
  hsa-miR-126-5p   Prostate cancer                                              51       89       8124       19747      0.001488647   0.254558697
  hsa-miR-126-5p   Pancreatic cancer                                            44       75       8124       19747      0.001614467   0.274459422
  hsa-miR-126-5p   Renal cell carcinoma                                         42       71       8124       19747      0.001632088   0.277455025
  hsa-miR-126-5p   T cell receptor signaling pathway                            61       110      8124       19747      0.001662737   0.282665317
  hsa-miR-126-5p   Axon guidance                                                70       129      8124       19747      0.001728524   0.293849129
  hsa-miR-126-5p   Wnt signaling pathway                                        79       152      8124       19747      0.004369155   0.642265816
  hsa-miR-126-5p   Melanoma                                                     40       71       8124       19747      0.00685062    0.897431176
  hsa-miR-126-5p   Focal adhesion                                               101      203      8124       19747      0.007764884   0.978375349
  hsa-miR-126-5p   VEGF signaling pathway                                       41       78       8124       19747      0.027028017   1
  hsa-miR-126-5p   ECM receptor interaction                                     43       84       8124       19747      0.039640345   1
  hsa-miR-126-5p   GnRH signaling pathway                                       52       105      8124       19747      0.05015675    1
  hsa-miR-126-5p   Progesterone mediated oocyte maturation                      44       88       8124       19747      0.057399498   1
  hsa-miR-126-5p   ABC transporters                                             26       44       8124       19747      0.012230769   1
  hsa-miR-126-5p   Endometrial cancer                                           28       52       8124       19747      0.043389343   1
  hsa-miR-126-5p   Non homologous end joining                                   9        13       8124       19747      0.038757914   1
  hsa-miR-126-5p   Adipocytokine signaling pathway                              39       70       8124       19747      0.009610695   1
  hsa-miR-126-5p   B cell receptor signaling pathway                            39       75       8124       19747      0.037002266   1
  hsa-miR-126-5p   Primary immunodeficiency                                     20       35       8124       19747      0.040787619   1
  hsa-miR-126-5p   Cell adhesion molecules CAMs                                 68       133      8124       19747      0.012382036   1
  hsa-miR-126-5p   Cell cycle                                                   64       124      8124       19747      0.011604645   1
  hsa-miR-126-5p   Acute myeloid leukemia                                       31       58       8124       19747      0.038959432   1
  hsa-miR-126-5p   Drug metabolism other enzymes                                29       51       8124       19747      0.016791375   1
  hsa-miR-126-5p   PPAR signaling pathway                                       36       70       8124       19747      0.052375031   1
  hsa-miR-126-5p   Starch and sucrose metabolism                                29       52       8124       19747      0.023271708   1
  hsa-miR-126-5p   mTOR signaling pathway                                       29       53       8124       19747      0.03154144    1
  hsa-miR-126-5p   Aldosterone regulated sodium reabsorption                    25       42       8124       19747      0.012305735   1
  hsa-miR-126-5p   Tight junction                                               64       132      8124       19747      0.052078934   1
  hsa-miR-126-5p   Porphyrin and chlorophyll metabolism                         25       41       8124       19747      0.008117058   1
  hsa-miR-126-5p   Regulation of actin cytoskeleton                             99       212      8124       19747      0.057272856   1
  hsa-miR-126-5p   Protein export                                               14       23       8124       19747      0.044570896   1
  hsa-miR-22-5p    Pathways in cancer                                           257      330      11812      19747      1.83E-12      3.56E-10
  hsa-miR-22-5p    Axon guidance                                                110      129      11812      19747      2.59E-10      5.00E-08
  hsa-miR-22-5p    Endocytosis                                                  149      187      11812      19747      4.95E-09      9.40E-07
  hsa-miR-22-5p    Wnt signaling pathway                                        124      152      11812      19747      6.55E-09      1.24E-06
  hsa-miR-22-5p    MAPK signaling pathway                                       207      272      11812      19747      8.91E-09      1.69E-06
  hsa-miR-22-5p    Colorectal cancer                                            75       86       11812      19747      2.35E-08      4.45E-06
  hsa-miR-22-5p    Cell adhesion molecules CAMs                                 108      133      11812      19747      9.92E-08      1.85E-05
  hsa-miR-22-5p    ErbB signaling pathway                                       76       89       11812      19747      1.37E-07      2.56E-05
  hsa-miR-22-5p    Neurotrophin signaling pathway                               103      129      11812      19747      9.50E-07      0.000173927
  hsa-miR-22-5p    Focal adhesion                                               154      203      11812      19747      9.68E-07      0.000177219
  hsa-miR-22-5p    Chronic myeloid leukemia                                     64       75       11812      19747      1.43E-06      0.000260548
  hsa-miR-22-5p    Small cell lung cancer                                       70       84       11812      19747      2.90E-06      0.000522275
  hsa-miR-22-5p    Glioma                                                       56       65       11812      19747      3.48E-06      0.000622806
  hsa-miR-22-5p    Type II diabetes mellitus                                    44       49       11812      19747      3.52E-06      0.000629532
  hsa-miR-22-5p    B cell receptor signaling pathway                            63       75       11812      19747      5.33E-06      0.000948843
  hsa-miR-22-5p    Prostate cancer                                              73       89       11812      19747      5.80E-06      0.00102714
  hsa-miR-22-5p    T cell receptor signaling pathway                            87       110      11812      19747      1.34E-05      0.002351804
  hsa-miR-22-5p    Leukocyte transendothelial migration                         91       116      11812      19747      1.57E-05      0.002744659
  hsa-miR-22-5p    Regulation of actin cytoskeleton                             156      212      11812      19747      1.73E-05      0.003024113
  hsa-miR-22-5p    Apoptosis                                                    70       87       11812      19747      3.23E-05      0.005550083
  hsa-miR-22-5p    Adherens junction                                            62       76       11812      19747      4.08E-05      0.006975744
  hsa-miR-22-5p    Pancreatic cancer                                            61       75       11812      19747      5.61E-05      0.009538741
  hsa-miR-22-5p    Fc gamma R mediated phagocytosis                             76       97       11812      19747      8.38E-05      0.014085998
  hsa-miR-22-5p    Endometrial cancer                                           44       52       11812      19747      0.000101849   0.017008724
  hsa-miR-22-5p    Ubiquitin mediated proteolysis                               101      134      11812      19747      0.000107433   0.017941347
  hsa-miR-22-5p    Insulin signaling pathway                                    104      139      11812      19747      0.00014148    0.023485705
  hsa-miR-22-5p    Non small cell lung cancer                                   45       54       11812      19747      0.000179093   0.029550271
  hsa-miR-22-5p    Melanogenesis                                                78       102      11812      19747      0.000288309   0.047282657
  hsa-miR-22-5p    VEGF signaling pathway                                       61       78       11812      19747      0.000454736   0.073212496
  hsa-miR-22-5p    Acute myeloid leukemia                                       47       58       11812      19747      0.000474205   0.076346974
  hsa-miR-22-5p    p53 signaling pathway                                        54       68       11812      19747      0.000481292   0.077197402
  hsa-miR-22-5p    Dorso ventral axis formation                                 22       24       11812      19747      0.000620089   0.098594229
  hsa-miR-22-5p    Melanoma                                                     55       71       11812      19747      0.001297563   0.197229622
  hsa-miR-22-5p    Calcium signaling pathway                                    125      178      11812      19747      0.002461358   0.356896943
  hsa-miR-22-5p    Long term potentiation                                       54       71       11812      19747      0.002984255   0.426748527
  hsa-miR-22-5p    Renal cell carcinoma                                         54       71       11812      19747      0.002984255   0.426748527
  hsa-miR-22-5p    Aldosterone regulated sodium reabsorption                    34       42       11812      19747      0.003015903   0.431274084
  hsa-miR-22-5p    Basal cell carcinoma                                         43       55       11812      19747      0.003152907   0.447712777
  hsa-miR-22-5p    Amyotrophic lateral sclerosis ALS                            43       55       11812      19747      0.003152907   0.447712777
  hsa-miR-22-5p    Lysine degradation                                           36       45       11812      19747      0.003356409   0.476610046
  hsa-miR-22-5p    Adipocytokine signaling pathway                              53       70       11812      19747      0.003848062   0.542576696
  hsa-miR-22-5p    mTOR signaling pathway                                       41       53       11812      19747      0.005514037   0.733366983
  hsa-miR-22-5p    Epithelial cell signaling in Helicobacter pylori infection   53       71       11812      19747      0.006391491   0.824502359
  hsa-miR-22-5p    Hypertrophic cardiomyopathy HCM                              63       86       11812      19747      0.006423679   0.828654588
  hsa-miR-22-5p    Arrhythmogenic right ventricular cardiomyopathy ARVC         55       74       11812      19747      0.006436624   0.830010217
  hsa-miR-22-5p    Chondroitin sulfate biosynthesis                             19       22       11812      19747      0.007196724   0.899590471
  hsa-miR-22-5p    Phosphatidylinositol signaling system                        56       76       11812      19747      0.0081223     0.966553692
  hsa-miR-22-5p    Prion diseases                                               28       35       11812      19747      0.009551427   1
  hsa-miR-22-5p    Heparan sulfate biosynthesis                                 21       26       11812      19747      0.020411929   1
  hsa-miR-22-5p    Fc epsilon RI signaling pathway                              58       82       11812      19747      0.026603879   1
  hsa-miR-22-5p    GnRH signaling pathway                                       73       105      11812      19747      0.025144507   1
  hsa-miR-22-5p    Chemokine signaling pathway                                  128      189      11812      19747      0.014802878   1
  hsa-miR-22-5p    N Glycan biosynthesis                                        35       46       11812      19747      0.01561363    1
  hsa-miR-22-5p    TGF beta signaling pathway                                   62       86       11812      19747      0.0120408     1
  hsa-miR-22-5p    Hedgehog signaling pathway                                   40       56       11812      19747      0.048585074   1
  hsa-miR-22-5p    ABC transporters                                             33       44       11812      19747      0.026093417   1
  hsa-miR-22-5p    Type I diabetes mellitus                                     32       44       11812      19747      0.05300307    1
  hsa-miR-22-5p    Bladder cancer                                               33       43       11812      19747      0.015183097   1
  hsa-miR-22-5p    Jak STAT signaling pathway                                   108      156      11812      19747      0.009237744   1
  hsa-miR-22-5p    Valine leucine and isoleucine degradation                    33       45       11812      19747      0.04218212    1
  hsa-miR-22-5p    Long term depression                                         51       73       11812      19747      0.049326477   1
  hsa-miR-22-5p    SNARE interactions in vesicular transport                    30       39       11812      19747      0.019292832   1
  hsa-miR-22-5p    Caffeine metabolism                                          7        7        11812      19747      0.027380781   1
  hsa-miR-22-5p    Dilated cardiomyopathy                                       67       94       11812      19747      0.013884057   1
  hsa-miR-22-5p    Progesterone mediated oocyte maturation                      61       88       11812      19747      0.04174596    1
  hsa-miR-30b-5p   Pathways in cancer                                           156      330      6411       19747      1.23E-08      2.38E-06
  hsa-miR-30b-5p   Adherens junction                                            46       76       6411       19747      4.52E-07      8.67E-05
  hsa-miR-30b-5p   Colorectal cancer                                            49       86       6411       19747      2.38E-06      0.000450104
  hsa-miR-30b-5p   ErbB signaling pathway                                       50       89       6411       19747      3.30E-06      0.000623737
  hsa-miR-30b-5p   Glioma                                                       39       65       6411       19747      4.53E-06      0.000851658
  hsa-miR-30b-5p   Ubiquitin mediated proteolysis                               68       134      6411       19747      8.38E-06      0.001567818
  hsa-miR-30b-5p   Non small cell lung cancer                                   33       54       6411       19747      1.41E-05      0.002637103
  hsa-miR-30b-5p   Wnt signaling pathway                                        73       152      6411       19747      4.52E-05      0.008184389
  hsa-miR-30b-5p   Pancreatic cancer                                            41       75       6411       19747      5.81E-05      0.010463047
  hsa-miR-30b-5p   Chronic myeloid leukemia                                     41       75       6411       19747      5.81E-05      0.010463047
  hsa-miR-30b-5p   Axon guidance                                                63       129      6411       19747      7.86E-05      0.013994427
  hsa-miR-30b-5p   Phosphatidylinositol signaling system                        41       76       6411       19747      8.68E-05      0.015459153
  hsa-miR-30b-5p   Apoptosis                                                    45       87       6411       19747      0.000151014   0.026578382
  hsa-miR-30b-5p   MAPK signaling pathway                                       117      272      6411       19747      0.000158251   0.02785209
  hsa-miR-30b-5p   Long term potentiation                                       38       71       6411       19747      0.000193569   0.034068087
  hsa-miR-30b-5p   Melanoma                                                     38       71       6411       19747      0.000193569   0.034068087
  hsa-miR-30b-5p   Endocytosis                                                  84       187      6411       19747      0.000238243   0.041930686
  hsa-miR-30b-5p   Prostate cancer                                              45       89       6411       19747      0.000295855   0.052070558
  hsa-miR-30b-5p   Neurotrophin signaling pathway                               60       129      6411       19747      0.000594457   0.099868714
  hsa-miR-30b-5p   Long term depression                                         37       73       6411       19747      0.00092949    0.150577329
  hsa-miR-30b-5p   Amyotrophic lateral sclerosis ALS                            29       55       6411       19747      0.001463924   0.229836089
  hsa-miR-30b-5p   Regulation of actin cytoskeleton                             89       212      6411       19747      0.00218848    0.334837477
  hsa-miR-30b-5p   Renal cell carcinoma                                         35       71       6411       19747      0.00233667    0.357510548
  hsa-miR-30b-5p   Melanogenesis                                                47       102      6411       19747      0.002785731   0.42343105
  hsa-miR-30b-5p   Endometrial cancer                                           27       52       6411       19747      0.002814214   0.424946331
  hsa-miR-30b-5p   Focal adhesion                                               85       203      6411       19747      0.002953579   0.44599037
  hsa-miR-30b-5p   Gap junction                                                 42       90       6411       19747      0.003411486   0.511722866
  hsa-miR-30b-5p   Progesterone mediated oocyte maturation                      41       88       6411       19747      0.003926434   0.585346476
  hsa-miR-30b-5p   Acute myeloid leukemia                                       29       58       6411       19747      0.004116963   0.613427489
  hsa-miR-30b-5p   Protein export                                               14       23       6411       19747      0.004720087   0.703292942
  hsa-miR-30b-5p   O Glycan biosynthesis                                        17       30       6411       19747      0.005327257   0.788434095
  hsa-miR-30b-5p   Arrhythmogenic right ventricular cardiomyopathy ARVC         35       74       6411       19747      0.005487362   0.806642248
  hsa-miR-30b-5p   Inositol phosphate metabolism                                27       54       6411       19747      0.005531749   0.813167132
  hsa-miR-30b-5p   Aldosterone regulated sodium reabsorption                    22       42       6411       19747      0.005864446   0.862073569
  hsa-miR-30b-5p   mTOR signaling pathway                                       26       53       6411       19747      0.008761618   1
  hsa-miR-30b-5p   Ascorbate and aldarate metabolism                            14       26       6411       19747      0.019511549   1
  hsa-miR-30b-5p   Type II diabetes mellitus                                    24       49       6411       19747      0.011815574   1
  hsa-miR-30b-5p   p53 signaling pathway                                        30       68       6411       19747      0.029133167   1
  hsa-miR-30b-5p   Small cell lung cancer                                       38       84       6411       19747      0.009658053   1
  hsa-miR-30b-5p   T cell receptor signaling pathway                            47       110      6411       19747      0.015157895   1
  hsa-miR-30b-5p   Leukocyte transendothelial migration                         49       116      6411       19747      0.016941064   1
  hsa-miR-30b-5p   Cell adhesion molecules CAMs                                 53       133      6411       19747      0.043304347   1
  hsa-miR-30b-5p   Vascular smooth muscle contraction                           50       116      6411       19747      0.010372332   1
  hsa-miR-30b-5p   Thyroid cancer                                               16       29       6411       19747      0.009556352   1
  hsa-miR-30b-5p   Insulin signaling pathway                                    59       139      6411       19747      0.008447402   1
  hsa-miR-30b-5p   ABC transporters                                             20       44       6411       19747      0.048992968   1
  hsa-miR-30b-5p   TGF beta signaling pathway                                   39       86       6411       19747      0.008411963   1
  hsa-miR-30b-5p   Tight junction                                               55       132      6411       19747      0.016223801   1
  hsa-miR-30b-5p   Hypertrophic cardiomyopathy HCM                              36       86       6411       19747      0.042112097   1
  hsa-miR-30b-5p   Bladder cancer                                               20       43       6411       19747      0.03804409    1
  hsa-miR-30b-5p   Fc gamma R mediated phagocytosis                             42       97       6411       19747      0.016262241   1
  hsa-miR-30b-5p   Dilated cardiomyopathy                                       39       94       6411       19747      0.040911576   1
  hsa-miR-30b-5p   Calcium signaling pathway                                    73       178      6411       19747      0.00990428    1
  hsa-miR-30b-5p   Fc epsilon RI signaling pathway                              37       82       6411       19747      0.011088588   1
  hsa-miR-660-5p   Chronic myeloid leukemia                                     47       75       5834       19747      2.75E-09      5.30E-07
  hsa-miR-660-5p   Pathways in cancer                                           145      330      5834       19747      1.63E-08      3.12E-06
  hsa-miR-660-5p   Glioma                                                       41       65       5834       19747      2.14E-08      4.08E-06
  hsa-miR-660-5p   Insulin signaling pathway                                    71       139      5834       19747      7.71E-08      1.46E-05
  hsa-miR-660-5p   Apoptosis                                                    49       87       5834       19747      1.69E-07      3.19E-05
  hsa-miR-660-5p   MAPK signaling pathway                                       119      272      5834       19747      4.01E-07      7.50E-05
  hsa-miR-660-5p   ErbB signaling pathway                                       49       89       5834       19747      4.34E-07      8.11E-05
  hsa-miR-660-5p   Non small cell lung cancer                                   33       54       5834       19747      1.44E-06      0.000268502
  hsa-miR-660-5p   Pancreatic cancer                                            41       75       5834       19747      4.73E-06      0.000864782
  hsa-miR-660-5p   Renal cell carcinoma                                         39       71       5834       19747      6.86E-06      0.001248947
  hsa-miR-660-5p   Wnt signaling pathway                                        70       152      5834       19747      1.17E-05      0.002111246
  hsa-miR-660-5p   Adipocytokine signaling pathway                              38       70       5834       19747      1.30E-05      0.002331179
  hsa-miR-660-5p   Small cell lung cancer                                       43       84       5834       19747      2.51E-05      0.004445646
  hsa-miR-660-5p   Neurotrophin signaling pathway                               60       129      5834       19747      3.33E-05      0.005852361
  hsa-miR-660-5p   Aldosterone regulated sodium reabsorption                    25       42       5834       19747      5.11E-05      0.008849739
  hsa-miR-660-5p   Prostate cancer                                              44       89       5834       19747      6.07E-05      0.010434751
  hsa-miR-660-5p   Calcium signaling pathway                                    77       178      5834       19747      6.61E-05      0.011367391
  hsa-miR-660-5p   Axon guidance                                                59       129      5834       19747      7.01E-05      0.012062999
  hsa-miR-660-5p   Vascular smooth muscle contraction                           54       116      5834       19747      7.81E-05      0.01334723
  hsa-miR-660-5p   VEGF signaling pathway                                       39       78       5834       19747      0.000114223   0.019189454
  hsa-miR-660-5p   Dilated cardiomyopathy                                       45       94       5834       19747      0.000133217   0.022247276
  hsa-miR-660-5p   Hypertrophic cardiomyopathy HCM                              41       86       5834       19747      0.000290082   0.046703244
  hsa-miR-660-5p   Ether lipid metabolism                                       21       36       5834       19747      0.000300946   0.048452314
  hsa-miR-660-5p   Adherens junction                                            37       76       5834       19747      0.000335452   0.053672279
  hsa-miR-660-5p   Long term potentiation                                       35       71       5834       19747      0.000356024   0.056963838
  hsa-miR-660-5p   Melanoma                                                     35       71       5834       19747      0.000356024   0.056963838
  hsa-miR-660-5p   Type II diabetes mellitus                                    26       49       5834       19747      0.000474592   0.075460141
  hsa-miR-660-5p   T cell receptor signaling pathway                            49       110      5834       19747      0.000588087   0.092917806
  hsa-miR-660-5p   Colorectal cancer                                            40       86       5834       19747      0.000640805   0.10124723
  hsa-miR-660-5p   Heparan sulfate biosynthesis                                 16       26       5834       19747      0.000700414   0.110665477
  hsa-miR-660-5p   Phosphatidylinositol signaling system                        36       76       5834       19747      0.00077014    0.12091191
  hsa-miR-660-5p   Fc epsilon RI signaling pathway                              38       82       5834       19747      0.000942721   0.148007141
  hsa-miR-660-5p   Chondroitin sulfate biosynthesis                             14       22       5834       19747      0.000946761   0.148641411
  hsa-miR-660-5p   B cell receptor signaling pathway                            35       75       5834       19747      0.001262727   0.195722739
  hsa-miR-660-5p   GnRH signaling pathway                                       46       105      5834       19747      0.001305999   0.202429883
  hsa-miR-660-5p   Glycerophospholipid metabolism                               33       70       5834       19747      0.001386882   0.214966783
  hsa-miR-660-5p   Endometrial cancer                                           26       52       5834       19747      0.001513571   0.23460344
  hsa-miR-660-5p   alpha Linolenic acid metabolism                              12       19       5834       19747      0.002432594   0.36245658
  hsa-miR-660-5p   Acute myeloid leukemia                                       27       58       5834       19747      0.004528781   0.638558156
  hsa-miR-660-5p   Ubiquitin mediated proteolysis                               54       134      5834       19747      0.004925757   0.689605994
  hsa-miR-660-5p   Tight junction                                               53       132      5834       19747      0.005783875   0.798174774
  hsa-miR-660-5p   Regulation of actin cytoskeleton                             80       212      5834       19747      0.006113676   0.84368735
  hsa-miR-660-5p   mTOR signaling pathway                                       24       53       5834       19747      0.010883105   1
  hsa-miR-660-5p   Oocyte meiosis                                               43       112      5834       19747      0.027327133   1
  hsa-miR-660-5p   Cell adhesion molecules CAMs                                 52       133      5834       19747      0.011277543   1
  hsa-miR-660-5p   Glycerolipid metabolism                                      19       46       5834       19747      0.059110806   1
  hsa-miR-660-5p   Keratan sulfate biosynthesis                                 8        15       5834       19747      0.045846187   1
  hsa-miR-660-5p   Gap junction                                                 35       90       5834       19747      0.035823644   1
  hsa-miR-660-5p   Chemokine signaling pathway                                  67       189      5834       19747      0.045513457   1
  hsa-miR-660-5p   Melanogenesis                                                40       102      5834       19747      0.022771607   1
  hsa-miR-660-5p   TGF beta signaling pathway                                   34       86       5834       19747      0.029933866   1
  hsa-miR-660-5p   Endocytosis                                                  68       187      5834       19747      0.025812976   1
  hsa-miR-660-5p   Toll like receptor signaling pathway                         39       105      5834       19747      0.05651642    1
  hsa-miR-660-5p   Thyroid cancer                                               13       29       5834       19747      0.058252127   1
  hsa-miR-660-5p   Fc gamma R mediated phagocytosis                             39       97       5834       19747      0.015811658   1
  hsa-miR-660-5p   SNARE interactions in vesicular transport                    18       39       5834       19747      0.020642828   1
  hsa-miR-660-5p   Long term depression                                         31       73       5834       19747      0.012611827   1
  hsa-miR-660-5p   Progesterone mediated oocyte maturation                      35       88       5834       19747      0.025436504   1
  hsa-miR-660-5p   Inositol phosphate metabolism                                22       54       5834       19747      0.051713668   1
  hsa-miR-660-5p   p53 signaling pathway                                        28       68       5834       19747      0.026708436   1
  hsa-miR-660-5p   Arrhythmogenic right ventricular cardiomyopathy ARVC         30       74       5834       19747      0.028017892   1
  hsa-miR-660-5p   Focal adhesion                                               76       203      5834       19747      0.009166013   1
  hsa-miR-660-5p   Jak STAT signaling pathway                                   58       156      5834       19747      0.023864483   1
  hsa-miR-660-5p   Valine leucine and isoleucine degradation                    19       45       5834       19747      0.047463292   1
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![The expression level of the 9 miRNAs in HCs, NMOSD and RRMS separately, as well as the statistical significance among all groups. NMOSD -- neuromyelitis optica spectrum disorders; RRMS -- relapsing-remitting multiple sclerosis; HCs -- healthy controls. NMOSD (n=45), MS (n=17), HCs (n=20). The bar diagram shows the mean 2-ΔCT values and standard deviations. \* P\<0.05, \*\* P \<0.01, \*\*\* P\<0.001.](medscimonit-23-2565-g001){#f1-medscimonit-23-2565}

![The expression level of the 9 miRNAs in NMOSD-IC and NMOSD-non-IC, RRMS and HCs. NMOSD-IC -- NMOSD patients with intracranial lesions; NMOSD-non-IC --NMOSD patients without intracranial lesions. RRMS -- relapsing-remitting multiple sclerosis; HCs -- healthy controls. The bar diagram shows the mean 2-ΔCT values and standard deviations. \* P\<0.05, \*\* P\<0.01, \*\*\* P\<0.001.](medscimonit-23-2565-g002){#f2-medscimonit-23-2565}

![Discriminating power of miRNAs alone or in combination in differentiating NMOSD, RRMS from healthy controls and between subtypes (**A--C**), as well as differentiating intracranial lesions in NMOSD (**D**). Receiver operating characteristic curves (ROCs) were generated by plotting the sensitivity of the levels of these miRNAs against 1-specificity and calculating the area under the ROC curves (C statistic) for each population.](medscimonit-23-2565-g003){#f3-medscimonit-23-2565}

###### 

Clinical features of the studied subjects.

  Clinical feature                          NMOSD (n=45)   RRMS (n=17)   CIS (n=14)   HC (n=20)   P value           
  ----------------------------------------- -------------- ------------- ------------ ----------- ---------- ------ ------
  Female/male ratio                         6.5:1          1.4:1         2.5:1        9:1         0.02       0.53   0.08
  Age at study (year)                       40.9±12.8      31.2±9.3      46.4±17.3    44.7±9.8    0.01       0.25   0.06
  Age at onset (year)                       36.1±13.3      28.9±8.1      44.4±17.3    --          0.04              --
  Disease duration (year)                   4.9±6.6        3.8±4.6       1.8±5.3      --          0.49              --
  Relapse (time)                            3.4±2.1        2.2±0.9       --           --          0.03              --
  EDSS score at the last visit              3.4±2.0        2.4±1.1       2.4±1.2      --          0.06              --
  Ratio of visual impairment (≤0.1/\>0.1)   9:36           1:16          6:8          --          0.17              --
  Ratio of anti-AQP4-Ab positivity (±)      34/6           0/10          0/5          --          \<0.0001          --
  Ratio of autoantibody positivity (±)      15/21          1/14          0/10         --          0.002             --

###### 

Correlation between miRNA expression and the clinical features of NMOSD.

  Clinical features                Categorized comparisons                 miR- 15b-3p   miR- 22-5p   miR- 30b-5p   miR- 335-3p   miR- 101-5p   miR- 126-5p   miR- 223-5p   miR- 576-5p   miR- 660-5p
  -------------------------------- --------------------------------------- ------------- ------------ ------------- ------------- ------------- ------------- ------------- ------------- -------------
  Gender                           Female (n=39) *vs.* Male (n=6)          0.93          0.89         0.84          0.09          0.51          0.71          0.48          0.67          0.78
  Phase of clinical course         Active (n=30) *vs.* stable (n=15)       0.27          0.09         0.26          0.1           0.83          0.71          0.92          0.65          0.36
  Times of relapse                 ≤3 (n=25) *vs.* ≥4 (n=20)               0.67          0.34         0.09          0.87          0.44          0.3           0.05          **0.01**      0.08
  EDSS score                       ≤3 (n=23) *vs.* \>3 (n=22)              0.5           0.81         0.52          0.39          1             0.62          0.55          0.48          0.21
  Visual impairment                Yes (n=18) *vs.* No (n=27)              0.85          0.74         0.63          0.55          0.28          0.99          0.49          0.16          0.37
                                   ≤0.1 (n=9) *vs.* \>0.1 (n=36)           0.53          0.49         0.84          0.78          0.21          0.99          **0.04**      **0.003**     0.06
  AQP4-Ab(titre)                   Negative (n=6) *vs.* Positive (n=34)    0.71          0.47         0.65          0.44          0.32          0.48          0.4           0.48          0.7
                                   ≤1: 32 (n=20) *vs.* ≥1: 100 (n=20)      0.23          0.39         0.11          0.49          0.51          0.25          0.95          0.72          0.86
  Autoantibody                     Positive (n=14) *vs.* Negative (n=20)   0.52          0.31         0.94          0.77          0.43          0.17          0.8           0.44          0.44
  MRI enhancement                  Positive (n=13) *vs.* Negative (n=32)   0.31          0.26         0.14          0.18          0.09          0.21          0.49          0.5           0.22
  Spinal cord involved (segment)   \<6 (n=17) *vs.* \>6 (n=19)             0.36          0.38         0.23          0.62          0.59          0.91          0.68          0.64          0.66
  B lymphocyte prootion (%)        \<9.0 (n=8) *vs.* \>14.1 (n=12)         0.29          0.28         0.66          0.36          0.35          0.6           0.56          0.57          0.63
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